In Vitro Properties of BAL30072, a Novel Siderophore Sulfactam with Activity against Multiresistant Gram-Negative Bacilli
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BAL30072 is a new monocyclic β-lactam antibiotic belonging to the sulfactams. Its spectrum of activity against significant Gram-negative pathogens with β-lactam-resistant phenotypes was evaluated and was compared with the activities of reference drugs, including aztreonam, ceftazidime, cefepime, meropenem, imipenem, and piperacillin-tazobactam. BAL30072 showed potent activity against multidrug-resistant (MDR) Pseudomonas aeruginosa and Acinetobacter sp. isolates, including many carbapenem-resistant strains. The MIC 90 s were 4 μg/ml for MDR Acinetobacter spp. and 8 μg/ml for MDR P. aeruginosa , whereas the MIC 90 of meropenem for the same sets of isolates was >32 μg/ml. BAL30072 was bactericidal against both Acinetobacter spp. and P. aeruginosa , even against strains that produced metallo-β-lactamases that conferred resistance to all other β-lactams tested, including aztreonam. It was also active against many species of MDR isolates of the Enterobacteriaceae family, including isolates that had a class A carbapenemase or a metallo-β-lactamase. Unlike other monocyclic β-lactams, BAL30072 was found to trigger the spheroplasting and lysis of Escherichia coli rather than the formation of extensive filaments. The basis for this unusual property is its inhibition of the bifunctional penicillin-binding proteins PBP 1a and PBP 1b, in addition to its high affinity for PBP 3, which is the target of monobactams, such as aztreonam.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community
Pitout, J. D. D., Nordmann, P., Laupland, K. B., & Poirel, L. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki166 · Cited by 790
Cited by
Antibiotics and Bacterial Resistance in the 21st Century
Fair, R. J., & Tor, Y. (2014) · Perspectives in Medicinal Chemistry · doi:10.4137/pmc.s14459 · Cited by 1,955
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases
Munoz-Price, L. S., Poirel, L., Bonomo, R. A., Schwaber, M. J., Daikos, G. L., Cormican, M., Cornaglia, G., Garau, J., Gniadkowski, M., Hayden, M. K., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70190-7 · Cited by 1,627
β-Lactams and β-Lactamase Inhibitors: An Overview
Bush, K., & Bradford, P. A. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025247 · Cited by 1,412
Tzouvelekis, L. S., Markogiannakis, A., Psichogiou, M., Tassios, P. T., & Daikos, G. L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05035-11 · Cited by 1,191
Boucher, H. W., Talbot, G. H., Benjamin, D. K., Bradley, J., Guidos, R. J., Jones, R. N., Murray, B. E., Bonomo, R. A., Gilbert, D., & for the Infectious Diseases Society of America (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit152 · Cited by 700
The emerging NDM carbapenemases
Nordmann, P., Poirel, L., Walsh, T. R., & Livermore, D. M. (2011) · Trends in Microbiology · doi:10.1016/j.tim.2011.09.005 · Cited by 663
Metals to combat antimicrobial resistance
Frei, A., Verderosa, A. D., Elliott, A. G., Zuegg, J., & Blaskovich, M. A. T. (2023) · Nature Reviews Chemistry · doi:10.1038/s41570-023-00463-4 · Cited by 638
Natural product and natural product derived drugs in clinical trials
Butler, M. S., Robertson, A. A. B., & Cooper, M. A. (2014) · Nat. Prod. Rep. · doi:10.1039/c4np00064a · Cited by 602
Permeability Barrier of Gram-Negative Cell Envelopes and Approaches To Bypass It
Zgurskaya, H. I., López, C. A., & Gnanakaran, S. (2015) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00097 · Cited by 580
Targeting Antibiotic Resistance
Chellat, M. F., Raguž, L., & Riedl, R. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201506818 · Cited by 487
Antibiotics in the clinical pipeline in 2013
Butler, M. S., Blaskovich, M. A., & Cooper, M. A. (2013) · The Journal of Antibiotics · doi:10.1038/ja.2013.86 · Cited by 433
The Evolving Role of Chemical Synthesis in Antibacterial Drug Discovery
Wright, P. M., Seiple, I. B., & Myers, A. G. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201310843 · Cited by 426
Bush, K., & Fisher, J. F. (2011) · Annual Review of Microbiology · doi:10.1146/annurev-micro-090110-102911 · Cited by 419
New antibiotics for bad bugs: where are we?
Bassetti, M., Merelli, M., Temperoni, C., & Astilean, A. (2013) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-12-22 · Cited by 403
Ito, A., Sato, T., Ota, M., Takemura, M., Nishikawa, T., Toba, S., Kohira, N., Miyagawa, S., Ishibashi, N., Matsumoto, S., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01454-17 · Cited by 400
Ito, A., Nishikawa, T., Matsumoto, S., Yoshizawa, H., Sato, T., Nakamura, R., Tsuji, M., & Yamano, Y. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01405-16 · Cited by 352
Antibiotics in the clinical pipeline at the end of 2015
Butler, M. S., Blaskovich, M. A., & Cooper, M. A. (2017) · The Journal of Antibiotics · doi:10.1038/ja.2016.72 · Cited by 349
Antibiotics in the clinical pipeline in 2011
Butler, M. S., & Cooper, M. A. (2011) · The Journal of Antibiotics · doi:10.1038/ja.2011.44 · Cited by 272
Novel Strategies for the Treatment of Pseudomonas aeruginosa Infections
Wagner, S., Sommer, R., Hinsberger, S., Lu, C., Hartmann, R. W., Empting, M., & Titz, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01698 · Cited by 258
Wright, H., Bonomo, R. A., & Paterson, D. L. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.09.001 · Cited by 256
Han, S., Zaniewski, R. P., Marr, E. S., Lacey, B. M., Tomaras, A. P., Evdokimov, A., Miller, J. R., & Shanmugasundaram, V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013092107 · Cited by 166
McPherson, C. J., Aschenbrenner, L. M., Lacey, B. M., Fahnoe, K. C., Lemmon, M. M., Finegan, S. M., Tadakamalla, B., O'Donnell, J. P., Mueller, J. P., & Tomaras, A. P. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01345-12 · Cited by 91
Iron acquisition in the cystic fibrosis lung and potential for novel therapeutic strategies
Tyrrell, J., & Callaghan, M. (2016) · Microbiology · doi:10.1099/mic.0.000220 · Cited by 56
Siderophores: A Case Study in Translational Chemical Biology
LeBlanc, A. R., & Wuest, W. M. (2024) · Biochemistry · doi:10.1021/acs.biochem.4c00276 · Cited by 20
Structural insights into Cir-mediated killing by the antimicrobial protein Microcin V
Maurakis, S. A., O’Donnell, A. C., Botos, I., Ghirlando, R., Davies, B. W., & Buchanan, S. K. (2025) · Communications Biology · doi:10.1038/s42003-025-08846-7 · Cited by 3
Metadata
- Authors
- Page, M. G. P., Dantier, C., & Desarbre, E.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2010-06
- Volume
- 54
- Issue
- 6
- Pages
- 2291-2302
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2169641796
- Cited by
- 227
- References
- 1
- FWCI
- 8.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.